Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis
Phathom is a high-risk, high-upside GI disruptor with VOQUEZNA scaling rapidly toward profitability under protected exclusivity through 2032.
Overview
Phathom Pharmaceuticals is a commercial-stage GI-focused biotech whose sole revenue engine, VOQUEZNA, is disrupting acid suppression therapy in the U.S. VOQUEZNA offers rapid, potent, 24-hour acid control and superior healing versus traditional PPIs, addressing a major unmet need across Erosive GERD, Non-Erosive GERD, and H. pylori. With GERD affecting roughly 65 million Americans and prescription-treated patients numbering about 15 million annually, Phathom is pursuing a large, concentrated market where clinical differentiation is translating into rapid adoption.